TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22912456

Group type: EXPERIMENTAL
Intervention: Dietary choline supplementation at 2,960 mg/kg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dietary choline supplementation at 370 mg/kg
Number of subjects: 240
Study: 19330795

Group type: EXPERIMENTAL
Intervention: Venlafaxine SR (75-150 mg/die)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/die)
Number of subjects: 50
Study: 17848609

Group type: EXPERIMENTAL
Intervention: 150 ml wine (13 g alcohol) daily for 3 months
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nonalcoholic diet beer (control) daily for 3 months
Number of subjects: 109
Study: 15171814

Group type: EXPERIMENTAL
Intervention: Detection of specific serum autoantibodies associated with neurological paraneoplastic syndromes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characterization of anti-neuronal autoantibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voltage-gated ion channels as targets for autoantibodies
Number of subjects: 0
Study: 11780926

Group type: EXPERIMENTAL
Intervention: 100 mg BMS-193884
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 15512224

Group type: EXPERIMENTAL
Intervention: Low dose aspirin combined with fish oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose aspirin only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose aspirin combined with evening primrose oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Evening primrose oil alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fish oil alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 7884952

Group type: EXPERIMENTAL
Intervention: 15 mg/kg TNF‐alpha MAb
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg TNF‐alpha MAb
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study: 2229305

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) 120 mg oral
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms iv)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) plus GHRH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GHRH alone in diabetic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 30
Study: 651762

Group type: EXPERIMENTAL
Intervention: Reptilase (1 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31862699

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.05 mg/kg/day (maximum dose 2.5 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: E14 (delaying ethinylestradiol induction of puberty by 2 years)
Number of subjects: 92
Study: 31150800

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.75% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 15 ml of 0.75% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.75% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 ml and 15 ml of 0.75% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: R20, R15, and R10 groups
Number of subjects: 45
Study: 28321637

Group type: EXPERIMENTAL
Intervention: Concentric-only resistance training (dumbbell curls and shoulder presses, twice per week for 4 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 13
Study: 25905863

Group type: EXPERIMENTAL
Intervention: Folic acid and iron supplementation
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Folic acid, iron, and multivitamin supplementation
Number of subjects: 802

Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 802
Study: 23404919

Group type: EXPERIMENTAL
Intervention: Initial psychosocial functioning (parent-reported PedsQL School Functioning)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Changes in psychosocial functioning (PedsQL Social and Global Self-esteem)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Improvements in Physical Appearance Self-esteem
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Declines in Desire to be Thinner
Number of subjects: 258
Study: 20693490

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (SES) groups (measured by income)
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Subjective SES measures
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Objective SES measures
Number of subjects: 1223
Study: 19832114

Group type: COMPARATOR
Intervention: HAART-eligible/untreated (CD4 <250 cells/microL, no HAART received)
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: HAART-eligible/treated (CD4 <250 cells/microL, HAART received)
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: HAART-ineligible (CD4 ≥250 cells/microL)
Number of subjects: 2318

Group type: COMPARATOR
Intervention: HAART-eligible/treated vs HAART-eligible/untreated
Number of subjects: 2318
Study: 17576783

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg daily)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 15465746

Group type: EXPERIMENTAL
Intervention: Stearic acid (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Palmitic acid (P)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oleic acid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: C18:1 trans (T)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 16
Study: 11459728

Group type: EXPERIMENTAL
Intervention: Gadolinium enhanced 3D MR angiography (MRA)
Number of subjects: 41
Study: 9702848

Group type: EXPERIMENTAL
Intervention: Loop diuretics (bumetanide 1 mg daily and furosemide 40 mg daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Furosemide 40 mg daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9606629

Group type: EXPERIMENTAL
Intervention: Mometasone (M) mornings/dithranol (D) evenings (M/D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcipotriol (C) mornings/dithranol (D) evenings (C/D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dithranol (D) twice a day (D/D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups after 4 weeks
Number of subjects: 30
Study: 1890447

Group type: EXPERIMENTAL
Intervention: Ohmeda 2120 monitor
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sys Stat mode
Number of subjects: 16

Group type: COMPARATOR
Intervention: Arterial cannula
Number of subjects: 16
Study: 7121527

Group type: EXPERIMENTAL
Intervention: 175 J shocks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: 320 J shocks
Number of subjects: 249

Group type: COMPARATOR
Intervention: Survivors
Number of subjects: 249
Study: 30633218

Group type: COMPARATOR
Intervention: EMLA cream (2g on both shoulders)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Trigger point injection (2mL of 0.2% ropivacaine)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study: 29507777

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 2584
Study: 27089170

Group type: EXPERIMENTAL
Intervention: lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo-R-CHOP21 × 6
Number of subjects: 0
Study: 25006768

Group type: EXPERIMENTAL
Intervention: Socket grafting and polytetrafluoroethylene (PTFE) barrier
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Socket grafting, buccal overbuilding, and PTFE barrier
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Socket grafting, collagen barrier, and PTFE barrier
Number of subjects: 20

Group type: COMPARATOR
Intervention: Collagen plug (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 22443165

Group type: EXPERIMENTAL
Intervention: Liver transplantation from FAP donor (Group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Liver transplantation from non-FAP cadaveric donor (Group 2)
Number of subjects: 44
Study: 20398311

Group type: EXPERIMENTAL
Intervention: EcN 40 ml enema (10E8 EcN/ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EcN 20 ml enema (10E8 EcN/ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EcN 10 ml enema (10E8 EcN/ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18507881

Group type: EXPERIMENTAL
Intervention: Daily supplementation with vitamins/minerals (Pharmaton Kiddi) for 12 weeks
Number of subjects: 81
Study: 15969833

Group type: EXPERIMENTAL
Intervention: RR participants (remember both lists)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FR participants (forget the first list, remember the second list)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (RR and FR participants)
Number of subjects: 0
Study: 14581796

Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin (5 mg/kg every 8 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5% dextrose placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin
Number of subjects: 24
Study: 10654172

Group type: EXPERIMENTAL
Intervention: Early grid laser treatment
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Delayed grid laser treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 9115016

Group type: EXPERIMENTAL
Intervention: Countermatching using 3 controls per case
Number of subjects: 100

Group type: COMPARATOR
Intervention: Random sampling using 10 controls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Random sampling using 3 controls per case
Number of subjects: 100
Study: 8241496

Group type: EXPERIMENTAL
Intervention: All transretinoic acid (ATRA) combined with daunorubicin‐Ara C chemotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Daunorubicin‐Ara C chemotherapy
Number of subjects: 101
Study: 2883819

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31035469

Group type: EXPERIMENTAL
Intervention: Aquilea Colesterol® (nutraceutical combination)
Number of subjects: 40
Study: 30284506

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) of contralesional M1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Constraint therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both rTMS and constraint therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neither rTMS nor constraint therapy (control group)
Number of subjects: 45
Study: 26706610

Group type: EXPERIMENTAL
Intervention: Defunctioning loop ileostomy
Number of subjects: 166

Group type: COMPARATOR
Intervention: No ileostomy
Number of subjects: 166
Study: 25113835

Group type: EXPERIMENTAL
Intervention: SANGUINATE 80 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SANGUINATE 120 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SANGUINATE 160 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 24
Study: 22674050

Group type: EXPERIMENTAL
Intervention: Protocol AML02
Number of subjects: 351

Group type: COMPARATOR
Intervention: Patients aged 10 to 21 years
Number of subjects: 351
Study: 19462324

Group type: EXPERIMENTAL
Intervention: GABA chocolate (10 g with 28 mg GABA)
Number of subjects: 0
Study: 17804831

Group type: EXPERIMENTAL
Intervention: Enhanced counseling and support (six sessions of individual and family counseling, support group participation, continuous availability of ad-hoc telephone counseling)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406
Study: 15732861

Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 35

Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 35
Study: 11380066

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8355039

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE2) 50 micrograms administered 24 hours before chemotherapy (FAC)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo (PL) administered 24 hours before chemotherapy (FAC)
Number of subjects: 154
Study: 3320135

Group type: EXPERIMENTAL
Intervention: Sudocrem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc cream BP
Number of subjects: 0
Study: 29557719

Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policies (no specified limits on shift length or mandatory time off between shifts)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard duty-hour policies (2011 ACGME guidelines)
Number of subjects: 63
Study: 28851420

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (verum acupuncture)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 74
Study: 23486907

Group type: COMPARATOR
Intervention: Spironolactone (50 mg/day) plus placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spironolactone (50 mg/day) plus hydrochlorothiazide (25 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/day) plus placebo
Number of subjects: 60
Study: 23883613

Group type: EXPERIMENTAL
Intervention: Fully automated closed-loop therapy (model predictive control algorithm directing insulin and 20% dextrose infusion based on FreeStyle Navigator continuous subcutaneous glucose values, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local protocol with intravenous sliding-scale insulin (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fully automated closed-loop therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local protocol with intravenous sliding-scale insulin
Number of subjects: 24
Study: 21602550

Group type: EXPERIMENTAL
Intervention: Azosemide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 22
Study: 18648850

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ligasure vessel sealing system (LI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 150
Study: 17323835

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid stenting
Number of subjects: 0
Study: 12761258

Group type: EXPERIMENTAL
Intervention: Enalapril (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 44
Study: 10998076

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (GHRT) for 18 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (obese subjects matched for age, sex, and BMI)
Number of subjects: 8
Study: 9068509

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg 3 times daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 60
Study: 8409041

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG), n = 64
Number of subjects: 127

Group type: COMPARATOR
Intervention: Coronary angioplasty (PTCA), n = 63
Number of subjects: 127
Study: 2821056

Group type: EXPERIMENTAL
Intervention: alpha hANP (0.5 microgram/min for 180 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29465055

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (empty socket)
Number of subjects: 50
Study: 28577673

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical care plus microfinance groups only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group medical visits only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group medical visits integrated into microfinance groups
Number of subjects: 0
Study: 25709689

Group type: EXPERIMENTAL
Intervention: Role play education
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lecture group (Control)
Number of subjects: 67
Study: 23470329

Group type: EXPERIMENTAL
Intervention: Web-based intervention (Reduce Your Use program)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control condition (6 modules of web-based educational information on cannabis)
Number of subjects: 225
Study: 21146883

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 208
Study: 19531812

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10001

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10001
Study: 17284911

Group type: EXPERIMENTAL
Intervention: Chewing gums containing calcium (dicalcium phosphate, calcium gluconate, calcium lactate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chewing gum containing casein phosphopeptide-amorphous calcium phosphate nanocomplexes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 15
Study: 14967716

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 496

Group type: COMPARATOR
Intervention: UFH+phenprocoumon
Number of subjects: 496
Study: 11328912

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 13
Study: 9220178

Group type: EXPERIMENTAL
Intervention: Angina pectoris during the first month following discharge
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Angina pectoris and heart failure
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 803
Study: 8381847

Group type: EXPERIMENTAL
Intervention: 7 gm/day of an 85% n-3 fatty acid concentrate for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 14
Study: 3546466

Group type: EXPERIMENTAL
Intervention: 5 mg metaproterenol aerosol solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 mg metaproterenol aerosol solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 mg metaproterenol aerosol solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5 mg metaproterenol aerosol solution (repeated)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 31891539

Group type: EXPERIMENTAL
Intervention: HIGHCAL diet (hypercaloric +50% caloric intake, high-saturated fat 11% energy, simple carbohydrates 54% energy)
Number of subjects: 13

Group type: COMPARATOR
Intervention: ISOCAL diet (isocaloric, moderate saturated fat 8% energy, carbohydrates 50% energy)
Number of subjects: 13
Study: 28946541

Group type: EXPERIMENTAL
Intervention: Balance training program
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) training program
Number of subjects: 22
Study: 27349618

Group type: EXPERIMENTAL
Intervention: Resin-based sealant
Number of subjects: 276

Group type: COMPARATOR
Intervention: Nontreatment group (no sealant)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: High individual caries risk (ICR) children with carious lesions ICDAS 3-6
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: SBDS program effectiveness based on carious lesions ICDAS 3-6
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Sealant retention
Number of subjects: 276
Study: 25128931

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (5 μg/min) without alpha-adrenergic blockade
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (5 μg/min) with phentolamine-induced non-selective blockade
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 21
Study: 23715032

Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20942650

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: zidovudine (ZDV) plus didanosine (ddI)
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: stavudine (d4T) plus lamivudine (3TC)
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: d4T+3TC
Number of subjects: 1771

Group type: COMPARATOR
Intervention: ZDV+ddI
Number of subjects: 1771
Study: 19020163

Group type: EXPERIMENTAL
Intervention: 20 mL of 1.5% mepivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 30 mL of 1% mepivacaine
Number of subjects: 90
Study: 17121036

Group type: EXPERIMENTAL
Intervention: Jingui Shenqi Pill plus prednisone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 30
Study: 12936972

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day once daily for 3 days (AZM-3)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day once daily for 6 days (AZM-6)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (AMC) 500-125 mg three times daily for 10 days
Number of subjects: 936
Study: 10506596

Group type: EXPERIMENTAL
Intervention: PIXY321 (375 microg/m(2) subcutaneously twice a day)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 8691829

Group type: EXPERIMENTAL
Intervention: Experimental condition with audience laughter present
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition with laughter absent
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 40
Study: 1996435

Group type: EXPERIMENTAL
Intervention: Nifedipine 5 mg administered sublingually
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6436526

Group type: EXPERIMENTAL
Intervention: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 9 g of phospholipids (PL) per day for 7 days.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 12 g of phospholipids (PL) per day for 7 days.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose administered alone as the sole source of nonprotein energy (glucose period).
Number of subjects: 12
Study: 30322353

Group type: EXPERIMENTAL
Intervention: Oral steroids (4-day course)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (4-day course)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Voice therapy (with or without steroids)
Number of subjects: 36